Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + exemestane + goserelin vs TAC as neoadjuvant therapy in premenopausal HR+ HER2- breast cancer (Phase 2)
ChiCTR2500106733Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dalpiciclib in breast cancer (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: objective response rate (ORR). Started Jul 2025; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500106733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106733.